Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (5915)	3/15/2002 3:27:24 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Crossy, I've never really followed the Japanese pharmas. Logically they should have done well given their (historic) low cost of capital and the substantial size of the Japanese market (about 40% of the US). My impression is that the Japanese version of the FDA is pretty bureaucratic - I believe the Japanese have only recently gotten a non-sedating antihistamine (Allegra) - I know that SGP has filed for Claritin approval but I don't think they have it yet (although I might have missed the approval). In terms of the quality of Japanese research, I've heard a US partner speak highly of Sankyo (who developed Pravachol). Peter